Abstract | BACKGROUND: CASE PRESENTATION: CONCLUSIONS: The laboratory and clinical findings as well as the marked improvement after high-dose methylprednisolone therapy suggest a post-infectious, immune-mediated cause of ataxia. This report should make clinicians aware to consider SARS-CoV-2 infection as a potential cause of post-infectious neurological deficits with an atypical clinical presentation and to consider high-dose corticosteroid treatment in case that a post-infectious immune-mediated mechanism is assumed.
|
Authors | Jana Werner, Ina Reichen, Michael Huber, Irene A Abela, Michael Weller, Ilijas Jelcic |
Journal | BMC infectious diseases
(BMC Infect Dis)
Vol. 21
Issue 1
Pg. 298
(Mar 24 2021)
ISSN: 1471-2334 [Electronic] England |
PMID | 33761897
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
|
Topics |
- COVID-19
(complications)
- Cerebellar Ataxia
(complications)
- Cerebrum
(diagnostic imaging)
- Humans
- Male
- Middle Aged
- RNA, Viral
|